|
US2021085765A1
|
|
Methods and compositions for pre-emptive treatment of graft versus host disease
|
|
WO2021028927A1
|
|
Combination of alpha-1-antitrypsin and steroids and uses therefor
|
|
WO2020157752A1
|
|
Pharmaceutical aerosol composition
|
|
WO2020026227A1
|
|
Methods and uses of alpha 1-antitrypsin for preservation of explanted organs
|
|
WO2019198070A1
|
|
Compositions and methods for treating inflammatory bowel diseases (ibds)
|
|
WO2019175877A1
|
|
Long-term treatment of diabetes
|
|
EP3735263A1
|
|
Methods and compositions for pre-emptive treatment of graft versus host disease
|
|
US2021008183A1
|
|
Methods of inducing immune tolerance and reducing anti-drug antibody response
|
|
EP3703733A1
|
|
Methods and compositions for reducing lung injury associated with lung transplantation
|
|
US2018371063A1
|
|
Therapy and prophylaxis of infectious disease caused by zika virus
|
|
US2020157242A1
|
|
Immunoglobulin compositions and process for obtaining the same
|
|
BR112019017438A2
|
|
use of alpha-1-antitrypsin
|
|
US2021085764A1
|
|
Dry powder formulations of alpha-1 antitrypsin
|
|
CA3040437A1
|
|
Multiple-variable dose regimen for treating diabetes
|
|
WO2017149528A1
|
|
Intrauterine therapy and prophylaxis of infectious diseases in a mammal fetus
|
|
EP3334441A1
|
|
Compositions derived from cohn fraction paste and use thereof
|
|
RU2472524C2
|
|
Alpha-1-antitrypsin for treating episodes of pulmonary disease aggravations
|
|
IL164642D0
|
|
Ultrapure transferrin for pharmaceutical compositions
|
|
AU2004273696A1
|
|
Large scale preparation of alpha-1 proteinase inhibitor and use thereof
|
|
IL158053D0
|
|
Process for large scale purification of alpha-1 proteinase inhibitor
|
